Daily Analysis on

CIPLA

Technical View

Stock has given a strong breakout above ₹1,580–1,590 with heavy volumes. Daily chart shows sharp bullish candles, supported by moving averages turning upward. Parabolic SAR has turned positive, indicating trend reversal. MACD crossing above the signal line, showing fresh bullish momentum. RSI near 66, still below overbought zone → room for further upside. Short-term support: ₹1,540 | Resistance: ₹1,620 – ₹1,650 If momentum sustains, stock may head towards ₹1,700–₹1,750 levels in the coming weeks. Upcoming Events & Impact USFDA inspection updates – any clearance will be a positive trigger. New drug launches in US & India may boost earnings visibility. Q2 FY26 results (Oct 2025) could be the next big driver. Why Stock Moved Today? Market buzz on positive USFDA approval for a key product. Fresh buying from institutional investors as pharma sector witnessed sectoral rotation. Breakout above major resistance levels attracted short-covering + momentum traders. Future Outlook If positive news sustains, Cipla can test ₹1,700–₹1,750 in near term. Medium-term target remains ₹1,850+, provided earnings growth & FDA updates remain supportive. Strong support zone now shifted to ₹1,500–₹1,520.